Investing.com -- Elevance Health’s Health Benefits operating profit collapsed in the second quarter of 2026, igniting a broad premarket selloff across the managed-care sector even as the insurer’s headline earnings handily beat estimates and full-year guidance was lifted.

Elevance shares are down 6.7% in premarket trade Thursday after the report showed adjusted operating margin fell to 3.6% from 5.0% year-over-year.

UnitedHealth Group, which reports its own Q2 results Thursday, saw its shares fall 2.7% in premarket trading, with investors bracing that Elevance’s Medicaid margin deterioration may prove sector-wide rather than company-specific.

Molina Healthcare, a pure-play Medicaid insurer, dropped as much as 9% in premarket — the steepest decline among major sector peers — bringing it sharply back from its 52-week high of $244.89 reached as recently as Tuesday’s session.

Humana declined roughly 1.7% in premarket, while Centene and CVS Health fell 4.9% and 2.3%, respectively.

Elevance posted Q2 2026 revenue of $50.47 billion, up 2.1% year-on-year and beating analyst consensus by 3.9%, while adjusted EPS of $7.45 came in roughly 20% above the $6.21 consensus estimate. Full-year adjusted EPS guidance was raised to at least $27.00.

On the surface, those numbers look strong. Beneath them, the picture is considerably more troubling.

The headline EPS figure was materially supported by an $0.80 per-share below-the-line benefit that flattered the reported result. Strip that out, and the core insurance business is under significant pressure.

The Health Benefits segment, Elevance’s largest, saw operating profit fall nearly half versus the prior year as lagging Medicaid reimbursement rates and an ongoing Medicare Advantage portfolio repositioning squeezed margins.

Management had previously guided investors to treat 2026 as a "trough year" for the segment, and the Q2 data validates that warning.

With Elevance’s non-recurring below-the-line support and front-loaded profitability, consensus implies a steep deceleration in core earnings power through the second half. Sell-side analysts project revenue to decline 2.3% over the next 12 months, a sharp contrast to the revenue growth posted in Q2.

Membership has also been gradually contracting, with the customer base slipping to 44.95 million in Q2 from 45.42 million the prior quarter, even as revenue per member has risen.

Prior to Wednesday’s earnings, Elevance shares had gained roughly 22% in 2026 through Monday’s close at $426.79, as the broader sector recovered from a stretch of medical loss ratios that exceeded 90% for many insurers through much of 2025. That recovery now faces its first serious test.